Showing results (271-280 of 407) with videos related to
Sort By:
Pageof 41
BMC Musculoskeletal Disorders|January 14, 2014
Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION studyHubert G Nüßlein, Rieke Alten, Mauro Galeazzi, et al.Journal of Immunology (Baltimore, Md. : 1950)|August 6, 2005
Heterozygous Arg753Gln polymorphism of human TLR-2 impairs immune activation by Borrelia burgdorferi and protects from late stage Lyme diseaseNicolas W J Schröder, Isabel Diterich, Antje Zinke, et al.Rheumatology International|February 11, 2020
Individual therapeutic DAS28-dcrit responses differentiate between effectiveness of rheumatoid arthritis therapies and reflect patient-reported outcomes: retrospective analysis of DAS28 responses in comparative tocilizumab studiesMichaela Koehm, Matthew J McIntosh, Michael W Hofmann, et al.Arthritis and Rheumatism|December 1, 2011
Tumor necrosis factor promoter polymorphism TNF*-857 is a risk allele for psoriatic arthritis independent of the PSORS1 locusEmiliano Giardina, Ulrike Hüffmeier, Jaya Ravindran, et al.Arthritis Research & Therapy|March 24, 2018
Antibodies against chemokine receptors CXCR3 and CXCR4 predict progressive deterioration of lung function in patients with systemic sclerosisFlorian Weigold, Jeannine Günther, Moritz Pfeiffenberger, et al.Drug Safety|February 2, 2020
An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational DataGerd R Burmester, Jeffrey R Curtis, Huifeng Yun, et al.Rheumatology and Therapy|January 5, 2024
Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 YearsChristina Charles-Schoeman, Jon T Giles, Nancy E Lane, et al.Arthritis and Rheumatism|June 10, 2004
Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trialJ Peter Kaltwasser, Peter Nash, Dafna Gladman, et al.RMD Open|August 31, 2023
Impact of different classes of immune-modulating treatments on B cell-related and T cell-related immune response before and after COVID-19 booster vaccination in patients with immune-mediated diseases and primary immunodeficiency: a cohort studyMichaela Koehm, Maximilian Klippstein, Stephanie Dauth, et al.Annals of the Rheumatic Diseases|June 29, 2012
Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated studyJacqueline Detert, Hans Bastian, Joachim Listing, et al.Pageof 41